Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Zoetis Inc    ZTS

Delayed Quote. Delayed  - 08/29 04:30:28 pm
50.77 USD   +0.02%
08/24 IMPLANTS : Your common questions answered
08/24 VALEANT PHARMAC : Pharma shake-up falls flat for investors
08/23DJNew CFO Tops Off Shake-Up At Valeant -- WSJ
News SummaryMost relevantAll newsSector news 

Zoetis Inc : APOQUEL® (oclacitinib tablet) Now Available to Treat ‘Itchy’ Dogs

share with twitter share with LinkedIn share with facebook
share via e-mail
01/20/2014 | 06:25pm CEST

FLORHAM PARK, N.J. - Jan. 20, 2014 - Zoetis Inc. today announced that APOQUEL® (oclacitinib tablet) is now available to veterinarians in the United States for the control of pruritus, or itching, associated with allergic dermatitis and the control of atopic dermatitis in dogs at least 12 months of age. With APOQUEL, veterinarians now have a first-in-class treatment choice that targets the itch of allergic skin conditions at its source. Canine itching is among the most frequent complaints of pet owners, affecting about one in six dogs whose owners seek veterinary help. About half of all itchy dogs will have an underlying allergic skin condition where APOQUEL would be indicated.

"When a dog develops an itch related to an allergy, it can be life-disrupting for the dog and the entire family. After gaining five years of experience with APOQUEL through my involvement in clinical trials, I've learned firsthand the difference this treatment can make to a dog and its owners in stopping the itch, but without many of the side effects that are common with steroids," said Thomas Lewis II, DVM, DACVD, practicing veterinary dermatologist at Dermatology for Animals in Gilbert, Ariz. He noted this has been the case even for those dogs that failed to respond to conventional therapies.

"Pet owners who complained that their dogs would wake them up in the middle of the night due to intense itch have told me that after treatment with APOQUEL, the household can sleep more peacefully," Dr. Lewis said. "In my 28 years of practice, this is the most exciting new treatment for the management of itch associated with allergic and atopic dermatitis in dogs, which can often be a challenging and complex condition to treat."

APOQUEL was approved by the U.S. Food and Drug Administration in May 2013 and is the first and only Janus kinase (JAK) inhibitor approved for veterinary use. Its novel mode of action specifically targets and inhibits the cytokines involved in itch and inflammation with minimal activity against cytokines involved in hematopoiesis or innate immune function. Clinical studies have shown that APOQUEL provides rapid relief from itching and improves inflammation in dogs that suffer from allergies, without many of the side effects commonly associated with steroids. In a trial of dogs with allergic dermatitis, APOQUEL produced rapid onset of efficacy within 24 hours. In a trial of dogs with atopic dermatitis, dogs treated with APOQUEL experienced a significant and long-term reduction in itch and inflammation at day 28 of the study. In cases where APOQUEL treatment was continued, success rates remained constant through day 112.

"Zoetis is committed to providing treatments for conditions that affect the lives of pets and their owners who care for them," said Mike McFarland, DVM, DABVP, Group Director, Companion Animal Veterinary Operations at Zoetis. "APOQUEL is just one example that shows how we are continuing to invest in innovative new approaches that help veterinarians address real-world conditions, such as allergic and atopic dermatitis."

For more information, please visit www.apoquel.com.

Important Safety Information

APOQUEL® should not be used in dogs less than 12 months of age or in dogs with serious infections. APOQUEL may increase the susceptibility to infection and demodicosis and may exacerbate neoplastic conditions. APOQUEL has not been evaluated in combination with systemic immunosuppressive agents such as glucocorticoids or cyclosporine. APOQUEL should not be used in breeding dogs, or pregnant or lactating dogs. The most common side effects seen in dogs administered APOQUEL were vomiting and diarrhea. APOQUEL has been safely used in conjunction with other common medications including antibiotics and parasiticides and with vaccinations. For Full Prescribing Information visit www.apoquel.com/Apoquel_PI.

About Zoetis

Zoetis (z

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ZOETIS INC
08/24 IMPLANTS : Your common questions answered
08/24 VALEANT PHARMACEUTICALS INTL : Pharma shake-up falls flat for investors
08/23DJNew CFO Tops Off Shake-Up At Valeant -- WSJ
08/22DJValeant Names Zoetis Executive as Financial Chief--Update
08/22DJValeant Names Zoetis Executive as Financial Chief--Update
08/22 VALEANT PHARMACEUTICALS INTL : Appoints Paul S. Herendeen As Executive Vice Pres..
08/22 VALEANT PHARMACEUTICALS INTL : Reportedly Appoints Zoetis` Executive Paul Herend..
08/22DJValeant Names Zoetis Executive as Financial Chief--Update
08/22DJValeant Names Zoetis Executive as CFO
08/22 ZOETIS INC. : Change in Directors or Principal Officers (form 8-K)
More news
Sector news : Veterinary Drugs
09:29aDJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
08/27 Stada shareholder AOC pushes through board reshuffle
08/27 ABBOTT LABORATORIES : Whiplashed investors stay skittish about St. Jude
08/26DJST JUDE MEDICAL : . Jude Denies Claims in Muddy Waters Report
More sector news : Veterinary Drugs
News from SeekingAlpha
08/22 WALL STREET BREAKFAST : Pfizer Closes In On $14B Takeover Of Medivation
08/22 Zoetis' CFO leaves company to join Valeant - DJ
08/18 Tracking George Soros's Portfolio - Q2 2016 Update
08/17 Tracking Bill Ackman's Pershing Square Portfolio - Q2 2016 Update
08/06 Pet Owners May Be Crazy About Their Pets, But Investors Should Avoid Overvalu..
Financials ($)
Sales 2016 4 879 M
EBIT 2016 1 540 M
Net income 2016 798 M
Debt 2016 3 541 M
Yield 2016 0,73%
P/E ratio 2016 31,58
P/E ratio 2017 24,32
EV / Sales 2016 5,88x
EV / Sales 2017 5,26x
Capitalization 25 128 M
More Financials
Duration : Period :
Zoetis Inc Technical Analysis Chart | ZTS | US98978V1035 | 4-Traders
Full-screen chart
Technical analysis trends ZOETIS INC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 54,5 $
Spread / Average Target 7,4%
Consensus details
EPS Revisions
More Estimates Revisions
Juan Ramón Alaix President, Chief Executive Officer & Director
Mike B. McCallister Non-Executive Chairman
Kristin C. Peck Executive Vice President & President-US Operations
Glenn David Chief Financial Officer & Executive Vice President
Catherine Ann Knupp Executive VP, President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ZOETIS INC5.93%25 128
VIRBAC-12.19%1 761
More Results